Self-renewal analysis of human AML-CB cotransplants with or without mobilization treatment
| AML Patient 3 | AML Patient 4 | AML Patient 5 | ||||
| Engraftment outcomes | Control | Mobilized | Control | Mobilized | Control | Mobilized |
| AML only | 0/4 | 0/3 | 0/3 | 0/5 | 1/1 | 2/5 |
| AML + CB | 4/4 | 3/3 | 2/3 | 1/5 | 0/1 | 2/5 |
| CB only | 0/4 | 0/3 | 1/3 | 4/5 | 0/1 | 1/5 |
| Total mice | 7 | 8 | 6 | |||
| AML Patient 3 | AML Patient 4 | AML Patient 5 | ||||
| Engraftment outcomes | Control | Mobilized | Control | Mobilized | Control | Mobilized |
| AML only | 0/4 | 0/3 | 0/3 | 0/5 | 1/1 | 2/5 |
| AML + CB | 4/4 | 3/3 | 2/3 | 1/5 | 0/1 | 2/5 |
| CB only | 0/4 | 0/3 | 1/3 | 4/5 | 0/1 | 1/5 |
| Total mice | 7 | 8 | 6 | |||
For each of three AML samples, it is indicated how many secondary transplant recipients were observed to have AML L-IC self-renewal, HSPC self-renewal, or both.